NMT Capital Mergers and Acquisitions Summary

Private Equity Firm Profile

NMT Capital’s most common sectors for investment arelife science (30%) and medical products (30%) . The Firm’s most common investment types include venture (100%). In total, NMT Capital has invested in 4 US states and 3 different countries.

In the last 3 years, NMT Capital has exited 1 company. The Firm’s most common exit type is trade sale (88%). NMT Capital’s largest (disclosed) exit occurred in 2019 when it sold MyoScience for $220M.

Join Mergr to view NMT Capital’s full profile and discover more small private equity firms just like it.

M&A Summary

  • M&A Total Activity18
    • M&A Buy Activity10
    • M&A Sell Activity8
  • Total Sectors Invested 6
  • Total Countries Invested 3
  • M&A Buy/Sell Connections 13

NMT Capital (Nexus)

400 Crown Colony Drive, Suite 104,
Quincy, Massachusetts 02169
United States
(617) 472-2805
www.nmtcapital.com
contact@nmtcapital.com

NMT Capital is a private equity firm focused on tech-oriented growth industries. Areas of interest include medical devices, diagnostics, biotechnology, specialty pharmaceutical, drug discovery tools, software, communications, information technology, and advanced materials. NMT Capital is based in Quincy, Massachusetts.


Investment Criteria

Sectors of Interest: Healthcare Services, Life Science, Manufacturing, Medical Products

Target Transaction Types: Buyout (LBO, MBO, MBI)

Geographic Preferences: East US, Midwest US, South US, West US, Canada

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size - -
Enterprise Value - -

M&A Summary

Buy vs Sell

Year ≤ '16 '17 '18 '19 '20 '21 T
Buy (0.0/yr) # 10 - - - - - 10
Sell (0.2/yr) # 7 - - 1 - - 8
vol $317M $220M $537M
  18

Most Recent M&A

Company Date Value Type
MyoScience, Inc. 2019-03-05 220M USD Add-on Acquisition
Fremont, California · www.iovera.com
Magellan Biosciences, Inc. 2016-03-24 - Add-on Acquisition
Chelmsford, Massachusetts · www.magellanbio.com
Spectra Analysis Instruments Inc. 2015-01-09 - Add-on Acquisition
Marlborough, Massachusetts · www.spectra-analysis.com
Selah Genomics, Inc. 2014-03-20 70M USD Add-on Acquisition
Greenville, South Carolina · www.selahgenomics.com
Presidio Pharmaceuticals, Inc. 2012-10-18 101M USD Merger
San Francisco, California · www.presidiopharma.com
Kiyatec, Inc. 2012-05-23 - Venture
Greenville, South Carolina · www.kiyatec.com
MyoScience, Inc. 2012-03-12 - Venture
Fremont, California · www.iovera.com
Cutanea Life Sciences, Inc. 2012-02-13 - Add-on Acquisition
Wayne, Pennsylvania · www.cutanealife.com
mtm Laboratories AG 2011-07-19 146M EUR Add-on Acquisition
Heidelberg, Germany
Spectra Analysis Instruments Inc. 2011-06-09 - Venture
Marlborough, Massachusetts · www.spectra-analysis.com
View All >>

M&A by Sector

Sector Current # Value All-time # Value
Life Science 1 (33%) - 3 (30%) -
Medical Products 1 (33%) - 3 (30%) -
Communications 1 (33%) - 1 (10%) -
Healthcare Services - - 1 (10%) -
Technology Hardware - - 1 (10%) -
Test/Measurement Equipment - - 1 (10%) -
Total 3 - 10 -

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 2 (67%) - 8 (80%) -
  Massachusetts - - 3 (30%) -
  South Carolina 2 (67%) - 2 (20%) -
  California - - 2 (20%) -
  Pennsylvania - - 1 (10%) -
United Kingdom 1 (33%) - 1 (10%) -
Germany - - 1 (10%) -
Domestic 2 (67%) - 8 (80%) -
Cross-border 1 (33%) - 2 (20%) -
Total 3 - 10 -

Acquisitions by Deal Type

Type Current # Value All-time # Value
Venture 3 (100%) - 10 (100%) -
Total 3 - 10 -

Exits by Deal Type

Type Total # Value
Trade Sale 4 (50%) -
Trade Sale - Public Company 3 (38%) 436M (81%)
Merger 1 (13%) 101M (19%)
Total 8 $537M

Deal Values

sell # Total
$100M to $1B 3 $467M
< $100M 1 $70M
TOTAL $537M
Largest MyoScience, Inc.
$220M (2019-03-05)

M&A Connections

Deals
Exited to
Strategic(s)
100%
8 (100%)

Investor Summary

Investor Type

Private Equity Firm

Size

Small

Specialist/Generalist

Generalist

Leadership

Gregory Zaic

Principal

Thomas Hancock

Principal

 Subscribe to unlock this and 171,438
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.2K Private Equity Firms
  • 161K M&A Transactions
  • 167K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.4K M&A Advisors
    (Investment Banks and Law Firms)
  • 59K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal